直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Collateral Estoppel May Bar Patentability of Substitute Claims in an IPR

August 8, 2024

Authored and Edited by Christina Ji-Hye Yang; Sonja W. Sahlsten; Matthew Weirich†

In ZyXEL Communications Corp. v. UNM Rainforest Innovations, No. 22-2220 (Fed. Cir. July 22, 2024), the Federal Circuit affirmed-in-part, reversed-in-part, and remanded-in-part the PTAB’s findings regarding U.S. Patent No. 8,265,096 (the “’096 patent”).

The ’096 patent relates to methods for constructing frame structures in orthogonal frequency-division multiple access (OFDMA) systems. In an IPR proceeding, the PTAB found claims 1-4, 6, and 7 unpatentable as obvious but found claim 8 not unpatentable. It also granted UNMRI’s contingent motion to amend, substituting new claims and finding them to be nonobvious. ZyXEL appealed, and UNMR cross-appealed.

The Federal Circuit affirmed that claims 1-4, 6, and 7 were unpatentable as obvious. But it reversed the Board’s non-obviousness ruling for claim 8, holding that a prior art reference need not explicitly articulate or express why its teachings are beneficial if a POSA would recognize that their application was beneficial. The Federal Circuit affirmed the PTAB’s decision to grant the motion to amend but remanded it for the Board to evaluate whether the substitute claims (which were a combination of claims 1-4 and 6-8, which were now all held to be unpatentable) are unpatentable under collateral estoppel. On remand, the Federal Circuit indicated that the Board may also consider whether the substitute claims are unpatentable based on a new prior art combination not previously raised.

Tags

patent-eligible, Patent Trial and Appeal Board (PTAB), United States Court of Appeals for the Federal Circuit (CAFC), Obviousness (35 USC § 103), estoppel

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

AI, Electronics, and Information Technology

Related Offices

Washington, DC

Contacts

Christina Ji-Hye Yang
Partner
Washington, DC
+1 202 408 4465
Email
Sonja W. Sahlsten
Partner
Washington, DC
+1 202 408 4329
Email

†Matthew Weirich is a Technical Specialist Intern at Finnegan.

Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

2026 Copyright Society Annual Meeting

June 14-16, 2026

Louisville

Seminar

3rd AI, IP, & Legal Forum

June 6, 2026

Shangai

Articles

California Reaches Record $12.75 Million CCPA Settlement with General Motors Over Driver Data

June 4, 2026

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP